|Bid||62.75 x 800|
|Ask||64.03 x 800|
|Day's Range||62.72 - 64.04|
|52 Week Range||48.12 - 69.62|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.95%|
Biotech funds tacked on $76 million this week, adding to more than $500 million in net inflows over the past two weeks — a phenomenon the group hasn't seen in nine months.
Biotech and pharma stocks dipped after the Senate's GOP tax reform leaves the fate of a key tax credit up in the air.
Biotechnology and pharmaceutical ETFs have rallied in recent weeks as drug pricing concerns wane and investors look to the opportunity of this market segment. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) ...
Up more than 42% year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI ) , one of the largest biotechnology ETFs, is one of this year's best-performing non-leveraged ETFs. That does not mean XBI's run ...
The SPDR S&P Biotech ETF (NYSEArca: XBI) , one of the largest biotechnology exchange traded funds, is getting in on the sector's resurgence. XBI, an equal-weight fund, is up about 7% over the past week, ...
Ionis entered a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA-targeted therapeutics in China in April 2017.